16.3 Pelvic Inflammatory Disease

Pelvic Inflammatory Disease (PID)

Pelvic Inflammatory Disease (PID) is an ascending, polymicrobial infection of the upper female genital tract, encompassing any combination of endometritis, salpingitis, tubo-ovarian abscess (TOA), and pelvic peritonitis. While N. gonorrhoeae and C. trachomatis are classic initiators, up to 60% to 70% of clinical cases are polymicrobial, involving vaginal anaerobes (Prevotella, Bacteroides), Mycoplasma genitalium, and enteric Gram-negative rods.

Pelvic Inflammatory Disease Diagnostic & Triage Pathway
├── Presumptive Minimum Clinical Criteria (At Least One Required with Pelvic Pain)
│   ├── 1. Cervical Motion Tenderness ("Chandelier Sign")
│   ├── 2. Uterine Fundal Tenderness
│   └── 3. Adnexal Tenderness (Unilateral or Bilateral)
├── Additional Supportive Criteria (Enhance Diagnostic Specificity)
│   ├── Oral Temperature >38.3°C (101.0°F)
│   ├── Abnormal Cervical Mucopurulent Discharge or Friability
│   ├── Abundant WBCs on Saline Vaginal Wet Mount (>10–20/HPF)
│   ├── Elevated Inflammatory Markers (ESR or C-Reactive Protein)
│   └── Positive NAAT for Neisseria gonorrhoeae or Chlamydia trachomatis
└── Triage: Inpatient Admission vs. Outpatient Management
    ├── Inpatient Indications: Surgical emergency not ruled out, Tubo-Ovarian Abscess,
    │   Pregnancy, Severe illness/peritonitis, Inability to tolerate oral fluids, Failed outpatient
    └── Outpatient Regimen: Ceftriaxone 500 mg IM + Doxycycline 100 mg BID x 14d + Metronidazole 500 mg BID x 14d
        └── MANDATORY: Clinical Reassessment within 48 to 72 Hours!

CDC Diagnostic Threshold (The "Low Bar" Rule)

Because irreversible tubal scaring occurs rapidly with subclinical or delayed therapy, the CDC mandates that clinicians maintain a low threshold for diagnosis and empiric treatment. Empiric antimicrobial therapy for PID must be initiated immediately in any sexually active young female presenting with lower abdominal or pelvic pain if no cause other than PID can be identified, and at least one of the following three minimum clinical criteria is present on bimanual pelvic examination:

1. Cervical Motion Tenderness (CMT): Exquisite pain elicited when the cervix is mobilized laterally during bimanual exam ("chandelier sign").
2. Uterine Tenderness: Pain upon direct bimanual palpation and compression of the uterine fundus.
3. Adnexal Tenderness: Direct palpation tenderness over one or both ovaries and fallopian tubes.

Outpatient Treatment Regimen

Patients who are hemodynamically stable, tolerating oral fluids, and have no evidence of tubo-ovarian abscess or peritonitis are managed in the outpatient setting:

• Ceftriaxone 500 mg IM in a single dose (1 g if weight ≥150 kg), PLUS
• Doxycycline 100 mg PO BID for 14 days, PLUS
• Metronidazole 500 mg PO BID for 14 days.
• Midwifery Rationale for Metronidazole: Metronidazole is mandatory to ensure complete anaerobic coverage and eradicate Trichomonas vaginalis, substantially reducing upper genital tract epithelial damage and chronic tubal scarring.
• The 48- to 72-Hour Rule: Outpatient management demands a mandatory clinical re-examination within 48 to 72 hours. If the patient demonstrates significant clinical improvement (defervescence, reduced pelvic tenderness, improved mobility), outpatient oral therapy is continued to complete the full 14-day course. If the patient has failed to improve or has worsened, immediate hospitalization for parenteral therapy and diagnostic imaging is required.

Inpatient Hospital Admission Criteria

Immediate hospital admission for parenteral broad-spectrum antibiotic therapy is required if:

1. Surgical emergencies (e.g., acute appendicitis, ruptured ovarian cyst, ectopic pregnancy) cannot be definitively excluded.
2. Suspected or ultrasound-confirmed Tubo-Ovarian Abscess (TOA).
3. Pregnancy: Pregnant individuals with PID face extreme risks of maternal sepsis, second-trimester loss, and preterm delivery; inpatient IV therapy is mandatory.
4. Severe illness, high fever (>38.5°C), persistent nausea, vomiting, or peritoneal signs (rebound tenderness, involuntary guarding).
5. Clinical failure of oral outpatient therapy after 48 to 72 hours.
6. Inability to tolerate, adhere to, or absorb outpatient oral regimens.

Long-Term Sequelae of PID

• Tubal Factor Infertility: Post-infectious salpingitis produces mucosal deciliation and luminal occlusion. The risk of permanent tubal infertility escalates exponentially with each subsequent episode: ~10% to 12% after a single episode, ~20% to 25% after two episodes, and ≥50% after three or more episodes.
• Ectopic Pregnancy: Endosalpingeal damage and intraluminal synechiae impede normal blastocyst transit, conferring a 6- to 10-fold increase in the risk of ectopic gestation.
• Chronic Pelvic Pain: Affects up to 30% of women, driven by extensive pelvic fibrous adhesions, hydrosalpinx, and recurrent pelvic congestion.
• Fitz-Hugh-Curtis Syndrome (Perihepatitis): Ascending transperitoneal tracking of infected exudate along the paracolic gutters into the subdiaphragmatic space. Manifests with severe, pleuritic right upper quadrant (RUQ) abdominal pain radiating to the right shoulder, friction rub over the liver, and normal liver transaminases. Laparoscopy demonstrates pathognomonic "violin-string" fibrinous adhesions between the anterior hepatic capsule and the peritoneal abdominal wall.

Differential Diagnosis

The low diagnostic threshold for PID means empiric treatment begins before certainty — but it does not license skipping the differential, because two of the alternatives are surgical emergencies:

The 72-Hour Rule & Treatment Failure

Re-evaluate every outpatient within 72 hours. Substantial clinical improvement — defervescence, reduced abdominal and adnexal tenderness, reduced cervical motion tenderness — should be evident by then.

Failure to improve within 72 hours requires hospitalization, parenteral therapy, and further imaging to look for a tubo-ovarian abscess or an alternative diagnosis. Continuing oral therapy and "giving it more time" in a patient who is not improving is the classic tested error.

Intrauterine Devices

Do not reflexively remove an IUD in a patient diagnosed with PID. Begin treatment with the device in place and reassess at 48 to 72 hours; removal is considered only if there is no clinical improvement. The historical association between IUDs and PID is largely confined to the first 3 weeks after insertion, when a pre-existing cervical infection can be carried upward; beyond that window the device does not raise the risk.

Partner Management & Follow-Up

• Treat sexual partners from the preceding 60 days — or the most recent partner if the last contact was longer ago — for gonorrhea and chlamydia, regardless of the partner's symptoms or test results. Use expedited partner therapy where state law permits it.
• Abstain from intercourse until both the patient and all partners have completed therapy and are symptom-free.
• Retest for gonorrhea and chlamydia at 3 months after treatment. This is a test for reinfection, which is common, not a test of cure — and it is the follow-up step most often omitted.
• Use the visit to offer HIV and syphilis testing, HIV pre-exposure prophylaxis counseling, HPV vaccination if indicated, and contraception, since a patient presenting with PID is by definition in a window of elevated sexual-health risk.